130 likes | 279 Views
Making Africa a competitor in the Global Pharmaceutical Industry: Implementation of the Pharmaceutical Manufacturing Plan for Africa. AWA Consultative Experts ’ Committee Meeting of Commission of the African Union, Nouakchott, Mauritania 27-28 May 2014 Dr Paul Lartey, FAPMA Chairperson.
E N D
Making Africa a competitor in the Global Pharmaceutical Industry: Implementation of the Pharmaceutical Manufacturing Plan for Africa AWA Consultative Experts’ Committee Meeting of Commission of the African Union, Nouakchott, Mauritania27-28 May 2014 Dr Paul Lartey, FAPMA Chairperson
Africa’s Public Health Challenges • Heavy burden of HIV/AIDS: top cause of morbidity and mortality in Sub-Sahara Africa; • Upsurge in tuberculosis and other opportunistic infections; • Future disease burden • 60 million people with hypertension by 2020 • 1 million cases of cancer annually • 18.6 million people with diabetes by 2020 • Other CVS, chronic respiratory diseases (COPD / asthma) and neuro-psychiatric conditions • NCD’s will have surpassed infectious diseases as the leading cause of death in Africa by 2030. Source: WHO, WHO AFRO, Frost & Sullivan analysis
Pharmaceutical Manufacturing Plan for Africa - PMPA • African Heads of State recognized the need for a sustainable strategy with treatment as central point • This in turn implies the need for readily available efficacious, high quality and affordable medicines • AU Heads of State meeting of July 2012 accepted the PMPA Business Plan
PMPA Vision To develop a competitive and enduring integrated pharmaceutical manufacturing industry in Africa, able to respond to the continent’s need for a secure and reliable supply of quality, affordable, accessible, safe and efficacious medicines.
PMPA: Partnering for Implementation • World health Organization (WHO) and United States Pharmacopeia convention’s Promoting the Quality of Medicines program. • These organizations are assisting with capacity development in regulation and GMP. • The United Nations Industrial Development Organization (UNIDO) is playing a much-needed coordinating role in the implementation of the PMPA BP, through a consortium comprising representation from all stakeholders. • Other partners are the United Nations Development Program (UNDP), the Joint United nations Program on HIV/AIDS (UNAIDS), United Nations Population Fund (UNFPA) and the African Development Bank.
Federation of African Pharmaceutical Manufacturers Associations • Member Organizations: • Federation of East African Pharmaceutical Manufacturers • Southern African Generic Medicines Association • West African Pharmaceutical Manufacturers Association
FAPMA Membership FAPMA 231 manufacturers
FAPMA Objectives • To promote excellence in the pharmaceutical industry • Promote access to safe, quality, efficacious medicines in Africa • To strengthen local production of medicines so as to meet needs of the continent • Facilitate economic growth through development of a sustainable, self-sufficient and viable pharmaceutical industry in Africa industry
Factors impacting on industry capacity • Unfair competition from fake and substandard imported medicines • Price competition against imported highly subsidized medicines from Asia • Inadequate patronage by African governments
Way Forward • Aligned visions of PMPA BP and FAPMA demonstrates commitment • Mix of capacity development measures, incentives and patronage, strengthen of 236 Africa-based pharmaceutical manufacturers Global competitiveness is imminently possible